EN DE
Watch Harvard Bioscience Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Harvard Bioscience Inc (HBIO) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Harvard Bioscience Inc stock $11.98, price $8.36, upside +43.3%, quality 42 out of 100. Rating: undervalued. Calculated from audited financials with 6 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

HB Harvard Bioscience Inc logo Thin data Nov 3, 2026

Harvard Bioscience Inc

HBIO · US
Speculative

The stock costs 30% less than our calculation considers fair.

Fair value $11.98 · Undervalued
Generates free cash flow
Even on cautious assumptions the value is 2% above the price ($8.55).
Quality 42/100
Mixed vs. peers (5/12)
Weak Growth (revenue 5y −3.3 %/yr in USD)
Loss-making · -11.9% net margin (TTM)
High debt
Narrow moat 13/100
Thin data
Watch Harvard Bioscience Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$84.70 $2.84 Fair Value $11.98 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.

How to read this chart

60‑month range $2.84 – $84.70 · fair‑value band $8.55 – $18.81 · the $8.36 price screens below the $11.98 fair value. As of Nov 3, 2026.

Follow Harvard Bioscience in your weekly email

Every Wednesday you see whether Harvard Bioscience is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally.

Show moreShow less

The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.

It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems.

The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories.

It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

Stock analysis

Harvard Bioscience Inc (HBIO) currently trades at $8.36, while our model-based Fair Value estimate is $11.98, implying the stock looks roughly 30% undervalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $14.44 per share, and 5 of the 6 models we run sit above the $8.36 price.

Bear case: the Multiples group reads lowest at $8.20, and 1 of the 6 models stay below the price. Data coverage for this calculation is low.

Scenario range: $8.55 (bear) to $18.81 (bull), the price of $8.36 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Harvard Bioscience Inc reported revenue of $86.6M in FY2025 versus $119M in FY2021, a compound −7.6%/yr. Reported net income was −$56.7M in FY2025.

Key figures

Market cap $37.8M Micro · P/S ratio 0.44 · EPS (TTM) $−2.32 · Net margin −11.9% · Return on equity −90.0% · Return on assets (EBIT) −1.6% (5-year average) · Operating margin −2.9% · Revenue (TTM) $87.8M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 13 out of 100 (medium confidence).

What moves the price

The share trades about 6% below its 52-week high and 94% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at 43%, HBIO screens cheaper than that median.

Fair Value models

Bear $8.55 Fair Value $11.98 Bull $18.81
Price $8.36 · Upside +43.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $11.00 $16.17 $24.87 80
Growth DCF $11.55 $16.46 $24.07 78
5Y Revenue Exit $7.24 $11.97 $18.81 71
All 6 models by family
DCF Models
FCF DCF $11.00 $16.17 $24.87 80
5Y Revenue Exit $7.24 $11.97 $18.81 71
10Y Revenue Exit $8.55 $11.98 $15.54 68
Multiples
EV/Revenue $3.39 $8.20 $13.01 50
Growth DCF
Growth DCF $11.55 $16.46 $24.07 78
Rev-Margin DCF $7.24 $12.41 $18.89 71

Open the full fair value analysis →

Quality Score breakdown

Overall quality 42/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 36
How much profit the company makes from its sales and capital
Quality Growth 20
Are margins and returns getting better?
Cashflow 52
Do the profits arrive as real cash?
Financial strength 12
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 11
How calm the share price moves, does not count
Price momentum 77
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 84
Distance to the 52-week high, does not count
New shares 61
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • BuyWilliam SniderDirector21,000 shares at $4.93$103,604Mar 17, 2026
  • BuyStephen J DenelskyDirector10,000 shares at $4.87$48,700Mar 17, 2026
  • BuyMark T FrostChief Financial Officer5,000 shares at $5.00$25,000Mar 16, 2026
  • BuyJohn D DukeChief Executive Officer, Director5,000 shares at $5.01$25,050Mar 16, 2026

Plus 5 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 18/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−8.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.3%
Start year 2020 (pandemic). Over 10 years: −2.2% a year
Revenue growth 27 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
0.2% (2020) → −0.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+10.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +8.2% a year for the price.

Watch HBIO, get fair value alerts →

Compare Harvard Bioscience Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks

Beats the industry median on 5/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 42 · Bottom 25%
Fair Value upside +43.3% · Top 25%
Profitability
Return on assets −70.8% · Bottom 25%
Net margin (12 months) −11.9% · Bottom 25%
Operating margin (12 months) −2.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 11.1% · Above median
Balance sheet
Debt / equity 2.61× · Highest 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 2.76× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 0.43× · Cheapest 25%
Price / free cash flow (fiscal year) 6.7× · Cheapest 25%
EV/EBITDA 8.8× · Cheaper than median
PEG 1.31× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)91 · sector 25
FUTURE (revenue growth)56 · sector 40
PAST (return on equity)0 · sector 30
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $90.38 $131.27 +45% vs HBIO
EssilorLuxottica Société anonyme EL €193.80 €196.22 +1% vs HBIO
Intuitive Surgical, Inc ISRG $452.80 $353.90 −22% vs HBIO
Medline Inc MDLN $39.64 $28.59 −28% vs HBIO
Alcon Inc ALC CHF 61.30 CHF 34.06 −44% vs HBIO
Becton, Dickinson and Company BDX $211.88 $97.80 −54% vs HBIO
Straumann Holding STMN CHF 104.50 CHF 45.50 −56% vs HBIO
West Pharmaceutical Services, Inc WST $399.81 $139.22 −65% vs HBIO
Sartorius Stedim Biotech S.A DIM €225.80 €54.82 −76% vs HBIO
Sartorius Aktiengesellschaft SRT €227.00 €42.50 −81% vs HBIO

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Harvard Bioscience Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Harvard Bioscience Inc Fair Value". https://www.fairvalue-calculator.com/stock/HBIO

Frequently asked questions

Is Harvard Bioscience Inc (HBIO) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of $11.98 versus a price of $8.36, about +43% upside (undervalued).
What is the fair value of HBIO?
Our model-based fair value for Harvard Bioscience Inc is $11.98 (as of Nov 3, 2026), built from audited fundamentals. The current price: $8.36.
What is the quality score of HBIO?
Harvard Bioscience Inc has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Harvard Bioscience Inc (HBIO)?
Our model-based price target is the fair value of $11.98 (as of Nov 3, 2026) from 6 valuation models. Cautious scenario $8.55, optimistic scenario $18.81. It is a calculation from audited fundamentals, not an analyst target.
What is the Harvard Bioscience Inc stock forecast for 2026?
Our models put fair value at $11.98, about +43% upside versus a price of $8.36 (undervalued). Cautious scenario $8.55, optimistic scenario $18.81. The calculation is refreshed regularly with new filings.
What is the revenue of Harvard Bioscience Inc (HBIO)?
Harvard Bioscience Inc reported trailing-twelve-month revenue of about $87.8M (latest available figure, as of Nov 3, 2026).
What growth is priced into Harvard Bioscience Inc (HBIO)?
For today's price to be fair in a discounted-cash-flow model, Harvard Bioscience Inc would have to grow free cash flow by +10.8 % per year for five years (discount rate 11.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -3.3 % per year. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of HBIO use?
Our models discount Harvard Bioscience Inc at 11.0 %: a base by market capitalisation (nano), damped by beta 1.51, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Harvard Bioscience Inc that is +10.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.0 %) and the same formula as our fair value.
How much growth has Harvard Bioscience Inc (HBIO) delivered so far?
Over the past 5 years revenue at Harvard Bioscience Inc grew -3.3 % a year. The price currently implies free-cash-flow growth of +10.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Harvard Bioscience Inc (HBIO) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Harvard Bioscience Inc (+10.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Harvard Bioscience Inc (HBIO)?
The free-cash-flow yield on the price is 14.84 %: that much free cash flow Harvard Bioscience Inc produces per unit of market value. When it exceeds the discount rate of our models (11.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Harvard Bioscience Inc (HBIO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Harvard Bioscience Inc it is $11.98 per share (as of Nov 3, 2026), against a price of $8.36. It is the blended result of 6 valuation models in 3 families (DCF Models, Multiples, Growth DCF).
Is Harvard Bioscience Inc stock overvalued or undervalued in 2026?
As of Nov 3, 2026, HBIO trades below its calculated fair value: price $8.36, fair value $11.98, a gap of about +43% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HBIO?
No. The price is what the market pays today ($8.36); the fair value is what the company's own numbers justify ($11.98). For Harvard Bioscience Inc the two are $3.62 per share apart. That gap is exactly why we show both numbers side by side.
How much is Harvard Bioscience Inc worth?
The market values Harvard Bioscience Inc at about $37.8M (market capitalisation, as of Nov 3, 2026). Per share that is $8.36; our models calculate a fair value of $11.98 per share.
What do the bullish and bearish scenarios say about HBIO?
Our models span a range for Harvard Bioscience Inc: cautious scenario $8.55, base $11.98, optimistic $18.81 per share (as of Nov 3, 2026, price $8.36). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of HBIO?
The PEG ratio of Harvard Bioscience Inc is 1.31 (P/E divided by earnings growth, as of Nov 3, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Harvard Bioscience Inc (HBIO)?
Balance-sheet figures for Harvard Bioscience Inc (as of Nov 3, 2026): return on equity −90.0%, debt of 2.61 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is HBIO from its 52-week high?
Harvard Bioscience Inc trades at $8.36, about 6% below its 52-week high of $8.90 and 94% above the low of $4.31 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $11.98 is for.
Which stocks are comparable to Harvard Bioscience Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Harvard Bioscience Inc stock attractive at the current price?
The data as of Nov 3, 2026: price $8.36, calculated fair value $11.98 (+43%), Quality Score 42/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HBIO calculated?
We run Harvard Bioscience Inc through 6 models from 3 families: DCF Models, Multiples, Growth DCF. Every model gets the same audited fundamentals; the fair value of $11.98 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Harvard Bioscience Inc currently trades 30% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Harvard Bioscience Inc (HBIO)?
The closing price on Nov 6, 2026 was $8.36. Our model-based fair value is $11.98, about +43% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Harvard Bioscience Inc right now?
The large discount to fair value meets weak quality (42/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($8.55). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($8.55 to $18.81) leaves room in how you read the outcome.

Key figures of Harvard Bioscience Inc

How large is the market capitalisation of Harvard Bioscience Inc (HBIO)?
The market capitalisation of Harvard Bioscience Inc is $37.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Harvard Bioscience Inc (HBIO)?
The price-to-sales ratio of Harvard Bioscience Inc is 0.44 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Harvard Bioscience Inc (HBIO)?
Earnings per share at Harvard Bioscience Inc are $−2.32. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Harvard Bioscience Inc (HBIO)?
The net margin of Harvard Bioscience Inc is −11.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Harvard Bioscience Inc (HBIO)?
The return on equity (ROE) of Harvard Bioscience Inc is −90.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Harvard Bioscience Inc (HBIO)?
On an EBIT basis the return on assets of Harvard Bioscience Inc is −1.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Harvard Bioscience Inc (HBIO)?
The operating margin of Harvard Bioscience Inc is −2.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Harvard Bioscience Inc (HBIO)?
Revenue at Harvard Bioscience Inc is growing +11.1% versus a year earlier (3y avg −8.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Harvard Bioscience Inc (HBIO)?
Earnings per share at Harvard Bioscience Inc are growing −80.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Harvard Bioscience Inc (HBIO) carry?
The net debt of Harvard Bioscience Inc is $35.7M (fiscal year 2025, ≈ 6.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Harvard Bioscience Inc in the live analysis

One click puts Harvard Bioscience Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.